Literature DB >> 17185180

Large-cell neuroendocrine carcinoma of the lung: an aggressive neuroendocrine lung cancer.

Felix G Fernandez1, Richard J Battafarano.   

Abstract

Large cell neuroendocrine carcinoma (LCNEC) is part of the neuroendocrine spectrum of pulmonary tumors. This increasingly recognized tumor has been reported to have 5-year actuarial survival rates following resection that are worse than those described for other variants of non-small cell lung cancer (NSCLC). Therefore, debate has emerged regarding whether the tumors should be classified and treated as NSCLC or small-cell lung cancer. This article reviews the tumor characterization, biology, presentation and diagnosis, surgical therapy, results of therapy, and long term prognosis of patients with LCNEC.

Entities:  

Mesh:

Year:  2006        PMID: 17185180     DOI: 10.1053/j.semtcvs.2006.08.007

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  16 in total

Review 1.  [Resection concepts for early stage neuroendocrine tumors of the lungs and bronchi].

Authors:  T Ploenes; C Aigner
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

2.  Intravitreal bevacizumab for iris tumor metastasized from large cell neuroendocrine carcinoma of lung.

Authors:  Hirotaka Yokouchi; Masayasu Kitahashi; Toshiyuki Oshitari; Shuichi Yamamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-19       Impact factor: 3.117

3.  First report of pulmonary large cell neuroendocrine carcinoma treated with stereotactic body radiation therapy.

Authors:  Shearwood McClelland; Gregory A Durm; Thomas J Birdas; Paul M Musto; Tim Lautenschlaeger
Journal:  Rep Pract Oncol Radiother       Date:  2019-09-02

4.  Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.

Authors:  Morena Fasano; Carminia Maria Della Corte; Federica Papaccio; Fortunato Ciardiello; Floriana Morgillo
Journal:  J Thorac Oncol       Date:  2015-08       Impact factor: 15.609

5.  Large cell neuroendocrine carcinoma of the lung presenting as pseudoachalasia: a case report.

Authors:  Ahmad Anaizi; Amna Rizvi-Toner; Jessica Valestin; Ron Schey
Journal:  J Med Case Rep       Date:  2015-03-12

6.  Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.

Authors:  Yuki Matsumura; Shigeki Umemura; Genichiro Ishii; Koji Tsuta; Shingo Matsumoto; Keiju Aokage; Tomoyuki Hishida; Junji Yoshida; Yuichiro Ohe; Hiroyuki Suzuki; Atsushi Ochiai; Koichi Goto; Kanji Nagai; Katsuya Tsuchihara
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-20       Impact factor: 4.553

7.  Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis.

Authors:  Qiao Yang; Zihan Xu; Xiewan Chen; Linpeng Zheng; Yongxin Yu; Xianlan Zhao; Mingjing Chen; Bangyu Luo; Jianmin Wang; Jianguo Sun
Journal:  Thorac Cancer       Date:  2019-02-07       Impact factor: 3.500

8.  Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.

Authors:  Zhen Zhou; Lei Zhu; Xiaomin Niu; Shengping Shen; Yi Zhao; Jie Zhang; Junyi Ye; Han Han-Zhang; Junjun Liu; Chenglin Liu; Shun Lu
Journal:  Thorac Cancer       Date:  2019-02-21       Impact factor: 3.500

9.  Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study.

Authors:  Ling Cao; Zhi-Wen Li; Min Wang; Ting-Ting Zhang; Bo Bao; Yun-Peng Liu
Journal:  PeerJ       Date:  2019-03-27       Impact factor: 2.984

10.  Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan.

Authors:  Shinichiro Ryuge; Shi-Xu Jiang; Mayuko Wada; Ken Katono; Maiko Iwasaki; Akira Takakura; Sakiko Otani; Yuka Kimura; Tomoya Fukui; Masanori Yokoba; Masaru Kubota; Masato Katagiri; Kazusige Hayakawa; Noriyuki Masuda
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.